Kyowa Kirin Co. Ltd. has partnered with Amgen Inc. to jointly develop and commercialize KHK-4083, Kyowa Kirin’s phase III-ready anti-OX40 fully human monoclonal antibody for the potential treatment of atopic dermatitis. Kyowa Kirin will receive a $400 million up front, while milestone payments could add an additional $850 million. Significant royalty payments on future global sales could sweeten the blockbuster deal.
Although 2020 is the highest money-making year on record for the biopharma industry, a direct comparison of the first five months indicates that the amount raised so far in 2021 is 22% ahead of last year, while the number of financings climbed 26%.
LONDON – Iksuda Therapeutics Ltd. sealed its transition from technology licensing company to antibody-drug conjugate (ADC) development specialist, closing a $47 million series A financing to move the lead program, IKS-03, into the clinic.
Scohia Pharma Inc. has secured an agreement with Huadong Medicine Co. Ltd., enabling the former to tap the greater China market for SCO-094, its GLP-1R and GIPR dual agonist.
Data presented at the American Society of Clinical Oncology's annual meeting, including: Antengene, Beigene, Coherus, Daiichi Sankyo, Hutchison China Meditech, Immutep, Innocare, Innovent Biologics, Junshi, Lyvgen, Origincell, Yingli.
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications, including: 4D, AB Science, Advaccine, Biogen, Bio-Thera Solutions, Brickell, Bridge, Celltrion Healthcare, Curevac, Hightide, Innovation, Kaken, Neuren, Qbiotics, Transcenta, Valneva.
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Akebia, Biontech, Celltrion Healthcare, Eli Lilly, Iaso, Innovent Biologics, Johnson & Johnson, Lannett Co., Micurx, Moderna, Neuren, Neurorx, Otsuka, Pfizer, Regeneron, Respirent, Visen.
In reporting positive data from a phase III study of sugemalimab in treating stage III non-small-cell lung cancer (NSCLC), Cstone Pharmaceuticals Co. Ltd. and Eqrx Inc. have the first anti-PD-L1 monoclonal antibody demonstrating progression-free survival in patients with concurrent or sequential chemoradiotherapy. The data built on positive data released in August from another phase III study showing sugemalimab (CS-1001) prolonged PFS when used as a first-line treatment for stage IV squamous and nonsquamous NSCLC plus standard-of-care chemotherapy, hitting the study’s primary endpoint.
RSS
